MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock through...
$19M
(533.33%↑ Y/Y)
Net cash provided by
financing activities
$17M
(325.00%↑ Y/Y)
Effect of changes in
exchange rates on cash and...
$1M
Canceled cashflow
$2M
Net decrease in
cash, cash...
-$688M
(-127.06%↓ Y/Y)
Canceled cashflow
$18M
Accrued liabilities
$464M
(221.78%↑ Y/Y)
Accounts receivable, net
-$114M
(59.29%↑ Y/Y)
Stock-based compensation
$104M
(-9.57%↓ Y/Y)
Depreciation and
amortization
$59M
(51.28%↑ Y/Y)
Prepaid expenses and
other assets
-$54M
(-17.39%↓ Y/Y)
Other liabilities
$26M
(-21.21%↓ Y/Y)
Right-of-use assets,
operating leases
-$11M
(-22.22%↓ Y/Y)
Inventory
-$6M
(-175.00%↓ Y/Y)
Other non-cash items
-$6M
(-200.00%↓ Y/Y)
Deferred revenue
$5M
(117.24%↑ Y/Y)
Loss on equity
investments, net
-$2M
(75.00%↑ Y/Y)
Proceeds from maturities
of marketable...
$732M
(-62.13%↓ Y/Y)
Proceeds from sales of
marketable securities
$602M
(-12.50%↓ Y/Y)
Tax payments
related to net share...
$2M
(100.00%↑ Y/Y)
Net cash used in
operating activities
-$630M
(39.25%↑ Y/Y)
Net cash (used in)
provided by investing...
-$76M
(-110.41%↓ Y/Y)
Canceled cashflow
$851M
Canceled cashflow
$1,334M
Net loss
-$1,343M
(-38.31%↓ Y/Y)
Purchases of marketable
securities
$1,348M
(-23.58%↓ Y/Y)
Accounts payable
-$120M
(23.08%↑ Y/Y)
Amortization/accretion of investments
$11M
(-42.11%↓ Y/Y)
Operating lease
liabilities
-$7M
(-40.00%↓ Y/Y)
Purchases of property,
plant and equipment
$62M
(-47.01%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)